Literature DB >> 19047063

The factor VIIIa C2 domain (residues 2228-2240) interacts with the factor IXa Gla domain in the factor Xase complex.

Tetsuhiro Soeda1, Keiji Nogami, Katsumi Nishiya, Masahiro Takeyama, Kenichi Ogiwara, Yoichi Sakata, Akira Yoshioka, Midori Shima.   

Abstract

Factor VIIIa functions as a cofactor for factor IXa in the phospholipid surface-dependent activation of factor X. Both the C2 domain of factor VIIIa and the Gla domain of factor IXa are involved in phospholipid binding and are required for the activation of factor X. In this study, we have examined the close relationship between these domains in the factor Xase complex. Enzyme-linked immunosorbent assay-based and surface plasmon resonance-based assays in the absence of phospholipid showed that Glu-Gly-Arg active site-modified factor IXa bound to immobilized recombinant C2 domain (rC2) dose-dependently (Kd = 108 nm). This binding ability was optimal under physiological conditions. A monoclonal antibody against the Gla domain of factor IXa inhibited binding by approximately 95%, and Gla domainless factor IXa failed to bind to rC2. The addition of monoclonal antibody or rC2 with factor VIIIa inhibited factor IXa-catalyzed factor X activation in the absence of phospholipid. Inhibition was not evident, however, in similar experiments in the absence of factor VIIIa, indicating that the C2 domain interacted with the Gla domain of factor IXa. A fragment designated C2-(2182-2259), derived from V8 protease-cleaved rC2, bound to Glu-Gly-Arg active site-modified factor IXa. Competitive assays, using overlapping synthetic peptides encompassing residues 2182-2259, demonstrated that peptide 2228-2240 significantly inhibited both this binding and factor Xa generation, independently of phospholipid. Our results indicated that residues 2228-2240 in the factor VIIIa C2 domain constitutes an interactive site for the Gla domain of factor IXa. The findings provide the first evidence for an essential role for this interaction in factor Xase assembly.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047063     DOI: 10.1074/jbc.M804955200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Modification of interdomain interfaces within the A3C1C2 subunit of factor VIII affects its stability and activity.

Authors:  Hironao Wakabayashi; Philip J Fay
Journal:  Biochemistry       Date:  2013-05-21       Impact factor: 3.162

2.  Membrane-binding properties of the Factor VIII C2 domain.

Authors:  Valerie A Novakovic; David B Cullinan; Hironao Wakabayashi; Philip J Fay; James D Baleja; Gary E Gilbert
Journal:  Biochem J       Date:  2011-04-01       Impact factor: 3.857

Review 3.  Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.

Authors:  Takehisa Kitazawa; Midori Shima
Journal:  Int J Hematol       Date:  2018-10-22       Impact factor: 2.490

4.  Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes.

Authors:  Justin D Walter; Rachel A Werther; Caileen M Brison; Rebecca K Cragerud; John F Healey; Shannon L Meeks; Pete Lollar; P Clint Spiegel
Journal:  Blood       Date:  2013-10-01       Impact factor: 22.113

5.  Dimeric Organization of Blood Coagulation Factor VIII bound to Lipid Nanotubes.

Authors:  Daniela Dalm; Jesus G Galaz-Montoya; Jaimy L Miller; Kirill Grushin; Alex Villalobos; Alexey Y Koyfman; Michael F Schmid; Svetla Stoilova-McPhie
Journal:  Sci Rep       Date:  2015-06-17       Impact factor: 4.379

6.  Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens.

Authors:  Takehisa Kitazawa; Keiko Esaki; Tatsuhiko Tachibana; Shinya Ishii; Tetsuhiro Soeda; Atsushi Muto; Yoshiki Kawabe; Tomoyuki Igawa; Hiroyuki Tsunoda; Keiji Nogami; Midori Shima; Kunihiro Hattori
Journal:  Thromb Haemost       Date:  2017-04-28       Impact factor: 5.249

Review 7.  The Molecular Basis of FIX Deficiency in Hemophilia B.

Authors:  Guomin Shen; Meng Gao; Qing Cao; Weikai Li
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

8.  SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa.

Authors:  Kenneth C Childers; Shaun C Peters; Pete Lollar; Harold Trent Spencer; Christopher B Doering; Paul C Spiegel
Journal:  Blood Adv       Date:  2022-06-14

9.  Structure of the Human Factor VIII C2 Domain in Complex with the 3E6 Inhibitory Antibody.

Authors:  Michelle E Wuerth; Rebecca K Cragerud; P Clint Spiegel
Journal:  Sci Rep       Date:  2015-11-24       Impact factor: 4.379

10.  Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor.

Authors:  Estelle K Ronayne; Shaun C Peters; Joseph S Gish; Celena Wilson; H Trent Spencer; Christopher B Doering; Pete Lollar; P Clint Spiegel; Kenneth C Childers
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.